The Cannabis Clinical Suite gives clinicians the decision support, drug interaction screening and dosing references that every other therapeutic category takes for granted. Drawing on a meta-analysis of 10,000+ peer-reviewed studies, it recommends the cannabinoid and terpene ratios the literature associates with each patient's stated needs, then scores every in-stock product nearby with a match percentage against that profile. Evidence instead of strain names and intuition. HIPAA-grade architecture, with or without an EMR.
Cannabis is a polypharmacy of cannabinoids, terpenes and phytochemicals. Clinical understanding is grounded in peer-reviewed studies and meta-analyses reporting significant results for each compound and for the synergies between them. Canalytics brings the decision support other therapeutic categories already have.
Validated cannabis clinical decision support at the depth of other therapeutic categories has not existed. Integrated interaction screening for patients on opioids, SSRIs, hypnotics or chemotherapy has required manual research. Recommendations often rely on strain name or THC percentage in the absence of a scored framework. Patients who under-report emotional symptoms can be missed without structured intake. Clinical documentation that is difficult to substantiate to a peer review standard.
A four-minute NIH-validated assessment and structured intake. A recommended cannabinoid and terpene profile with efficacy ratings, evidence strength and mechanism of action. Every formulary product scored 0 to 100% against each condition separately. Drug interaction analysis with four-level severity and clinical management guidance. Dosing, titration, contraindications and a scientific rationale narrative for the chart.
Ask why a product scores 91% for chronic back pain and get the cannabinoids, terpenes and receptor mechanisms behind the number, backed by our proprietary study database.
Intake, recommendation, safety screening, AI chat consultation and cancer chemovar alignment on one platform
A four-minute patient-reported outcomes assessment validated against the NIH PROMIS-29 framework produces T-scores across seven domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference and social participation. Combined with symptoms, conditions, medications, age, weight and history, it is standardized, quantitative, defensible clinical input.
A patient with pain, anxiety and insomnia gets three scores per product, not one averaged composite. Every product in your formulary is scored 0 to 100% against each detected condition separately, mirroring how you think about a multi-morbidity patient and showing exactly which product addresses which condition best.
The full medication list is screened automatically. Contraindication flags identify interactions and enzymatic pathways involved, severity is rated Minor, Moderate, Major or Contraindicated, and every flagged interaction comes with clinical management guidance, dose adjustment considerations and alternative therapy surfacing. The single largest barrier to confident recommendation, collapsed into one integrated check.
Recommended cannabinoid profile with per-compound efficacy rating, evidence strength, mechanism, onset, duration and key studies. Recommended terpene profile with entourage rationale. Administration method, starting dose, titration schedule, therapeutic window, maximum dose, patient-specific warnings and a scientific rationale narrative in clinically readable form.
Patients interact with the intake assistant through the AI Chat Assistant — trained on Canalytics' proprietary research of over 10,000 studies — by web, app, SMS or kiosk. The conversation converts into structured data the engine consumes. Patients with limited digital literacy get the same depth as a fully digital practice.
For cancer patients and palliative care, Cancer Chemovar Alignment identifies the chemovar profiles whose cannabinoid and terpene concentrations align most closely with what clinical research has documented for each cancer type — evaluated across 15+ cancer categories and ten weighted pathways with documented cannabinoid-terpene synergy modeling. Canalytics Business adds the deep analytical workstation: strain comparison and formulary curation.
The Cannabis Clinical Suite drives day-to-day clinical work. Business and Cancer Chemovar Alignment provide analytical depth for complex cases. Plant Match supports formulary curation and product substitution.
Intake, per-condition scoring, drug interaction analysis, dosing guidance and research-backed rationale in under 60 seconds.
Clinical NIH-validated assessment workflows, strain comparison and formulary analysis for complex cases.
Identifies the chemovar profiles whose cannabinoid and terpene concentrations clinical research most consistently associates with 15+ cancer types, evaluated across ten weighted pathways with synergy modeling.
Search genetic libraries for the closest chemovar match to a discontinued or out-of-stock product, ranked by cannabinoid and terpene similarity.
Patient outcome and formulary coverage analysis across a clinic or network.
Effect-based product access and wellness insights tracking for patients between visits.
Confidence, safety, documentation and reach, in that order
The barrier to recommending cannabis has been the absence of defensible decision support. A recommendation with per-condition scoring, interaction screening, dosing guidance and a research-backed rationale is clinical documentation that stands up to peer review, regulatory inquiry and the standard of care, and it lets you keep the patient you would otherwise refer out.
Patient populations seeking cannabis are defined by polypharmacy. Screening the full medication list against the recommended compounds, with contraindication flags and management guidance, replaces the cross-referencing of multiple databases that made every recommendation slow and every omission a risk.
A four-minute assessment and a sub-60-second recommendation mean the analytical load of a complex cannabis consultation moves off the clinician. The time goes to the patient conversation, and the same molecular-grade output is produced whether the clinic sees ten cannabis patients a month or a hundred.
EMR-independent by design. A standalone web interface with web, app, SMS and kiosk access means the same depth of recommendation is available in an integrated clinical group on Epic or Cerner, an independent practice or a rural clinic with no digital records at all. That is what makes consistent longitudinal cannabis guidance possible across fragmented networks and national programs.
From patient intake to a documented, formulary-scored recommendation
The patient completes the four-minute NIH-validated assessment plus symptoms, conditions, medications, age, weight and history, on screen or by voice. Free-form descriptions are converted into structured clinical data.
The Canalytics engine produces the recommended cannabinoid and terpene profile, scores every formulary product against each condition, screens the medication list and generates dosing and contraindications, all supported by a robust study database.
The clinician reviews per-condition product scores, interaction flags with management guidance, the dosing plan and the scientific rationale narrative, and adjusts with full visibility into why each result was produced.
Deliver the recommendation, retain the full documentation in the encrypted record, and track patient-reported outcomes longitudinally with the wellness insights engine. Outcomes refine the data the engine draws on.
Every consultation produces the record a cannabis recommendation should always have had
Every product Canalytics analyzes is scored across 30 therapeutic and adult use effects on a 0 to 10 scale, from the full cannabinoid and terpene fingerprint in its COA. This is the shared vocabulary that lets a breeder target an effect, a dispensary sort a shelf by it, a marketer write to it, and a clinician recommend against it.
Condition-relevant effects scored from receptor-level pharmacology, so clinical positioning and evidence-aligned recommendations rest on science.
Experience-relevant effects that predict how a product actually feels, so customers can shop by outcome instead of by strain name and THC percentage.
Beyond the effects shown above, Canalytics scores 17 additional therapeutic and adult use effects on every product, delivering the most complete effect profile in the industry and the depth needed to filter for what a customer wants and against what they want to avoid.
Every effect is quantified, not described. Products become sortable, comparable and rankable against any target.
Find high Calm and low Couchlock, or Focus without Anxiety. Score for the effects wanted and against the effects to avoid.
Cannabinoids and terpenes mapped to CB1, CB2, TRPV1, 5-HT1A, PPARγ, opioid μ and more, so scores rest on mechanism.
Every score is supported by a robust study database of peer-reviewed research. No black box.
Canalytics is a product-sorting tool, not a medical device. It does not diagnose, prescribe, treat, cure, or make any medical claim about cannabis or any condition, and it is not a substitute for a clinical evaluation, a physician visit, or any other medical care. Consistent with H.R. 8454, the Medical Marijuana and Cannabidiol Research Expansion Act, which protects state-licensed physicians discussing the known harms and benefits of cannabis with patients, Canalytics supports the recommendation conversation, never the prescription. That boundary is deliberate: it keeps the clinician, the clinic and Canalytics clear of unauthorized medical claims and FDA violations. The suite is available only in jurisdictions where it is lawful for licensed clinicians to discuss and recommend cannabis.
Bring cannabis recommendation up to the standard of the rest of your practice.
Run the Cannabis Clinical Suite standalone against a defined patient subset, typically pain, sleep, anxiety or complex polypharmacy cases, with the four-minute NIH-validated assessment as the standard intake. Add Business in month two for complex case depth and Cancer Chemovar Alignment for patients seeking research-aligned cannabis profiles for cancer support.